Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study

BACKGROUND: Current literature still lacks studies evaluating the effectiveness and safety of switching from Infliximab originator to SB2 biosimilar in Inflammatory Bowel Diseases (IBDs). We aimed to verify the ability of SB2 to maintain the clinical and biochemical response induced by originator af...

Full description

Saved in:
Bibliographic Details
Published in:Therap Adv Gastroenterol
Main Authors: Massimi, Davide, Barberio, Brigida, Bertani, Lorenzo, Costa, Francesco, Ferronato, Antonio, Facchin, Sonia, Cardin, Romilda, Cingolani, Linda, Casadei, Cesare, D’Incà, Renata, Zingone, Fabiana, Savarino, Edoardo Vincenzo
Format: Artigo
Language:Inglês
Published: SAGE Publications 2021
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8239954/
https://ncbi.nlm.nih.gov/pubmed/34249147
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17562848211023384
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items